Despite some recent declines, cardiovascular disease (CVD) remains the major cause of death in the United States and worldwide. Most recent advances in the treatment of CVD states have been produced by inhibition of mechanisms involved in disease progress. Many studies conducted in the last decade have illustrated increased biological oxidative pathways during CVD in animals and humans. Thus, increased production of reactive oxygen species may be a unifying mechanism in CVD progression, and antioxidants may have therapeutic value in this setting. In this review we address the following questions: Do oxidative mechanisms play a role in CVD? Where do the oxidants come from? What are the relevant oxidative events? What are the therapeutic implications?
|Number of pages||20|
|Journal||Pharmacology and Therapeutics|
|State||Published - 2001|
Bibliographical noteFunding Information:
This work was supported in part by a Research Fellowship from the Royal Thai Government (S. K. W.) and grants from the American Heart Association, Ohio-West Virginia Affiliates, and the National Institutes of Health (HL59791, DK55053, and HL63067).
- Cardiovascular disease
- Nitric oxide
- Reactive oxygen species
ASJC Scopus subject areas
- Pharmacology (medical)